Barchart
What Are Wall Street Analysts' Target Price for Biogen Stock?
📈
AI Sentiment
Highly Positive
8/10
- Home
- BIIB
BIIB
Biogen Inc.
as of 02-13-2026 3:46pm EST
$195.93
$0.05
-0.03%
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 24.2B | IPO Year: | 1991 |
| Target Price: | $195.13 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.79 | EPS Growth: | -21.38 |
| 52 Week Low/High: | $110.03 - $202.41 | Next Earning Date: | 02-06-2026 |
| Revenue: | $9,890,600,000 | Revenue Growth: | 2.22% |
| Revenue Growth (this year): | -3.81% | Revenue Growth (next year): | -0.38% |
| P/E Ratio: | 22.36 | Index: | |
| Free Cash Flow: | 2.1B | FCF Growth: | -24.65% |
AI-Powered BIIB Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 68.99%
68.99%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Biogen Inc. (BIIB)
Singhal Priya
Sell
Head of Development
BIIB Feb 9, 2026
Avg Cost/Share
$199.83
Shares
2,660
Total Value
$531,547.80
Owned After
8,043.143
SEC Form 4
Singhal Priya
Sell
Head of Development
BIIB Feb 2, 2026
Avg Cost/Share
$179.30
Shares
748
Total Value
$134,116.40
Owned After
8,043.143
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Singhal Priya | BIIB | Head of Development | Feb 9, 2026 | Sell | $199.83 | 2,660 | $531,547.80 | 8,043.143 | |
| Singhal Priya | BIIB | Head of Development | Feb 2, 2026 | Sell | $179.30 | 748 | $134,116.40 | 8,043.143 |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
MarketBeat
Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture
📊
AI Sentiment
Positive
6/10
BioPharma Dive
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
📈
AI Sentiment
Highly Positive
8/10
StockStory
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
📈
AI Sentiment
Highly Positive
8/10
StockStory
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
âž–
AI Sentiment
Neutral
4/10
Compare BIIB vs Leading Stocks
See how BIIB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.